Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In 2014, NAFLD was confirmed as the fastest growing aetiology for hepatocellular cancer in the USA. However, 2014 also saw progress in our understanding of the heritability and pathogenesis of NAFLD, and an important clinical trial targeting the farnesoid X receptor pathway has illustrated advances in developing a pharmacological therapy.
In 2014, pancreatic fibrosis has increasingly been recognized as a key determinant of the pathogenesis, therapy response and disease progression of chronic pancreatitis and pancreatic cancer. In addition, secretin-stimulated magnetic resonance cholangiopancreatography has gained increasing importance, especially in visualizing pancreatic duct abnormalities. However, the true imaging capacity has not been fully analysed.
